Recognizing and meeting the challenge of Chagas disease in the USA

References

• Hanford EJ, Zhan FB, Lu Y, Giordano A. Chagas disease in Texas: recognizing the significance and implications of evidence in the literature. Soc. Sci. Med.65, 60–79 (2007).
   PubMed Web of Science ®Google Scholar
• Kirchhoff L. Trypanosoma species (American trypanosomiasis, Chagas’ disease): biology of trypanosomes. In: Principles and Practice of Infectious Diseases (6th Edition). Mandell GL, Bennett JE, Dolin R (Eds). Elsevier Churchill Livingstone, Philadelphia, PA, USA, 3157–3163 (2005).
   Google Scholar
• Dias JC, Silveira AC, Schofield CJ. The impact of Chagas disease control in Latin America: a review. Mem. Inst. Oswaldo Cruz97, 603–612 (2002).
   PubMed Web of Science ®Google Scholar
• Reithinger R, Tarleton RL, Urbina JA, Kitron U, Gurtler RE. Eliminating Chagas disease: challenges and a roadmap. Br. Med. J.338, 1044–1046 (2009).
   Google Scholar
• Rassi A Jr, Dias JC, Marin-Neto JA, Rassi A. Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas’ disease. Heart95, 524–534 (2009).
   PubMedGoogle Scholar
• Pan American Health Organization. Quantitative estimate of Chagas disease in the Americas. PAHO, Montevideo, Uruguay (2006).
   Google Scholar
• Guzman-Bracho C. Epidemiology of Chagas disease in Mexico: an update. Trends Parasitol.17(8), 372–372 (2001).
   PubMed Web of Science ®Google Scholar
• Klotz SA, Dorn PL, Klotz JH et al. Feeding behavior of triatomines from the Southwestern United States: an update on potencial risk for transmission of Chagas disease. Acta Tropica111, 114–118 (2009).
   PubMedGoogle Scholar
• Dorn PL, Perniciaro L, Yabsley MJ et al. Autochthonous transmission of Trypanosoma cruzi, Louisiana. Emerg. Infect. Dis.13, 605–607 (2007).
   PubMedGoogle Scholar
• Bern C, Montgomery SP. An estimate of the burden of Chagas disease in the United States. Clin. Infect. Dis.49, e52–e54 (2009).
   PubMed Web of Science ®Google Scholar
• Viotti R, Vigliano C. Etiological treatment of chronic Chagas disease: neglected ‘evidence’ by evidence-based medicine. Expert. Rev. Anti Infect. Ther.5(4), 717–726 (2007).
   PubMed Web of Science ®Google Scholar
• Bern C, Montgomery SP, Herwaldt BL et al. Evaluation and treatment of Chagas disease in the United States. JAMA298(18), 2171–2181 (2007).
   PubMed Web of Science ®Google Scholar
• Milei J, Guerri-Guttenberg RA, Grana DR, Storino R. Prognostic impact of Chagas disease in the United States. Am. Heart J.157, 22–29 (2009).
   PubMed Web of Science ®Google Scholar
• Milei J, Mautner B, Storino RA, Sanchez JA, Ferrans VJ. Does Chagas’ disease exist as an undiagnosed form of cardiomyopathy in the United States? Am. Heart J.123, 1732–1735 (1992).
   PubMedGoogle Scholar
• Milei J, Fernandez AG, Vanzulli S et al. Myocardial inflammatory infiltrate in human chronic chagasic cardiomyopathy: immunohistochemical findings. Cardiovasc. Pathol.5, 209–19 (1996).
   PubMedGoogle Scholar
• Levy MZ, Bowman NM, Kawai V et al. Periurban Trypanosoma cruzi- infected Triatoma infestans, Arequipa, Peru. Emerg. Infect. Dis.12, 1345–1352 (2006).
   PubMedGoogle Scholar
• Fiorelli AI, Stolf NA, Honorato R et al. Later evolution after cardiac transplantation in Chagas’ disease. Transplant Proc.37(6), 2793–2798 (2005).
   PubMed Web of Science ®Google Scholar
• Altclas J, Sinagra A, Dictar M et al. Chagas disease in bone marrow transplantation: an approach to preemptive therapy. Bone Marrow Transplant36(2), 123–129 (2005).
   PubMed Web of Science ®Google Scholar
• Sartori AM, Ibrahim KY, Nunes Westphalen EV et al. Manifestations of Chagas disease (American trypanosomiasis) in patients with HIV/AIDS. Ann. Trop. Med. Parasitol.101(1), 31–50 (2007).
   PubMed Web of Science ®Google Scholar
• Vaidian AK, Weiss LM, Tanowitz HB. Chagas’ disease and AIDS. Kinetoplastid Biol. Dis.3(2), 2 (2004).
   PubMedGoogle Scholar
• Campos SV, Strabelli TM, Neto VA et al. Risk factors for Chagas’ disease reactivation after heart transplantation. J. Heart Lung Transplant.27(6), 597–602 (2008).
   PubMedGoogle Scholar
• Maguire JH. Trypanosoma. In: Infectious Diseases (3rd Edition). Gorbach SL, Bartlett JG, Blacklow NR (Eds). Lippincott Williams & Wilkins, PA, USA, 2327–2334 (2004).
   Google Scholar
• Torico F, Alonso-Vega C, Suarez E et al. Maternal Trypanosoma cruzi infection, pregnancy outcome, morbidity, and mortality of congenitally infected and non-infected newborns in Bolivia. Am. J. Trop. Med. Hyg.70(2), 201–209 (2004).
   PubMedGoogle Scholar
• Wegner DH, Rohwedder RW. The effect of nifurtimox in acute Chagas’ infection. Arzneimittelforschung22(9), 1624–1635 (1972).
   PubMedGoogle Scholar
• Junqueira AC, Chiari E, Wincker P. Comparison of the polymerase chain reaction with two classical parasitological methods for the diagnosis of Chagas disease in an endemic region of north-eastern Brazil. Trans. R. Soc. Trop. Med. Hyg.90, 129–132 (1996).
   PubMed Web of Science ®Google Scholar
• Castro AM, Luquetti AO, Rassi A, Rassi GG, Chiari E, Galvao LM. Blood culture and polymerase chain reaction for the diagnosis of the chronic phase of human infection with Trypanosoma cruzi.Parasitol Res.88(10), 894–900 (2002).
   PubMed Web of Science ®Google Scholar
• Chang CD, Cheng KY, Jiang LX et al. Evaluation of a prototype Trypanosoma cruzi antibody assay with recombinant antigens on a fully automated chemiluminescence analyzer for blood donor screening. Transfusion46, 1737–1744 (2006).
   PubMedGoogle Scholar
• Ferreira AW, Belem ZR, Lemos EA, Reed SG, Campos-Neto A. Enzyme-linked immunosorbent assay for serological diagnosis of Chagas’ disease employing a Trypanosoma cruzi recombinant antigen that consists of four different peptides. J. Clin. Microbiol.39, 4390–4395 (2001).
   PubMedGoogle Scholar
• WHO Expert Committee. Control of Chagas Disease. WHO, Brasilia, Brazil, WHO technical report series 905 (2002).
   Google Scholar
• Bern C, Montgomery SP, Katz L, Caglioti S, Stramer SL. Chagas disease and the US blood supply. Curr. Opin. Infect. Dis.21, 476–482 (2008).
   PubMedGoogle Scholar
• Dodd RY, Leiby DA. Emerging infectious threats to the blood supply. Annu. Rev. Med.55, 191–207 (2004).
   PubMed Web of Science ®Google Scholar
• Young C, Losikoff P, Chawla A, Glasser L, Forman E. Transfusion-acquired Trypanosoma cruzi infection. Transfusion47, 540–544 (2007).
   PubMedGoogle Scholar
• Otani MM, Vinelli E, Kirchoff LV et al. WHO comparative evaluation of serologic assays for Chagas disease. Transfusion49, 1076–1082 (2009).
   PubMedGoogle Scholar
• Leiby DA, Wendel S, Takaoka DT, Fachini RM, Oliveira LC, Tibbals MA. Serologic testing for Trypanosoma cruzi: comparison of radioimmunoprecipitation assay with commercially available indirect immunofluorescence assay, indirect hemagglutination assay, and enzyme-linked immunosorbent assay kits. J. Clin. Microbiol.38(2), 639–642 (2000).
   PubMed Web of Science ®Google Scholar
• Silveira-Lacerda EP, Silva AG, Junior SF et al. Chagas’ disease: application of TESA-blot inconclusive sera from a Brazilian blood bank. Vox Sang.87, 204–207 (2004).
   PubMedGoogle Scholar
• Leiby DA, Herron RM Jr, Read EJ, Lenes BA, Stumpf RJ. Trypanosoma cruzi in Los Angeles and Miami blood donors: impact of evolving donor demographics on seroprevalence and implications for transfusion transmission. Transfusion42, 549–555 (2002).
   PubMed Web of Science ®Google Scholar
• CDC. Blood donor screening for Chagas disease – United States. MMWR Morb. Mortal. Wkly Rep.56, 141–143 (2007).
   PubMedGoogle Scholar
• Garratty G, Glynn SA, McEntire R. ABO and Rh(D) phenotype frequencies of different racial/ethnic groups in the United States. Transfusion44, 703–706 (2004).
   PubMed Web of Science ®Google Scholar
• Viotti R, Vigliani C, Lococo B et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment. Ann. Intern. Med.144, 724–734 (2006)
   PubMed Web of Science ®Google Scholar
• Garcia S, Ramos CO, Senra JF et al. Treatment with benznidazole during the chronic phase of experimental Chagas disease decreases cardiac alterations. Antimicrob. Agents Chemother.9, 1521–1528 (2005).
   Google Scholar
• Rodriques CJ, de Castro SL. A critical review on Chagas disease chemotherapy. Mem. Inst. Oswaldo Cruz97(1), 3–24 (2002).
   PubMed Web of Science ®Google Scholar
• de Andrade AL, Zicker F, de Oliveira RM et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet348(9030), 1407–1413 (1996).
   PubMed Web of Science ®Google Scholar
• Sosa Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas’ disease. Am. J. Trop. Med. Hyg.58(4), 526–529 (1998).
   Google Scholar
• Coura JR, de Abreu LL, Willcox HP, Petana W. Comparative controlled study on the use of benznidazole, nifurtimox and placebo, in the chronic form of Chagas’ disease, in a field area with interrupted transmission: preliminary evaluation. Rev. Soc. Bras. Med. Trop.30(2), 139–144 (1997).
   PubMedGoogle Scholar
• Ferreira RC, Ferreira LC. Mutagenicity of nifurtimox and benznidazole in the Salmonella microsoma assay. Br. J. Med. Biol. Res.19(1), 19–25 (1986).
   PubMedGoogle Scholar
• Gorla NB, Ledesma OS, Barbieri GP, Larripa IB. Thirteenfold increase of chromosomal aberrations nonrandomly distributed in chagasic children treated with nifurtimox. Mutat. Res.224(2), 263–267 (1989).
   PubMed Web of Science ®Google Scholar
• Teixeira AR, Cordoba JC, Souto Maior I, Solorzano E. Chagas’ disease: lymphoma growth in rabbits treated with benznidazole. Am. J. Trop. Med. Hyg.43(2), 146–158 (1990).
   PubMedGoogle Scholar
• Teixeira AR, Silva R, Cunha Neto E, Santana JM, Rizzo LV. Malignant, non-Hodgkin’s lymphomas in Trypanosomoa cruzi-infected rabits treated with nitroarenes. J. Comp. Pathol.103(1), 37–48 (1990).
   PubMedGoogle Scholar
• Kirchhoff LV. Chagas disease: american trypanosomiasis. Infec. Dis. Clin. North Am.7(3), 487–502 (1993).
   PubMedGoogle Scholar
• Rassi Jr A, Rassi A, Little WC et al. Development and validation of a risk score for predicting death in Chagas heart disease. N. Engl. J. Med.355, 799–808 (2006).
   PubMed Web of Science ®Google Scholar
• Rassi Jr A, Rassi SG, Rassi A. Sudden death in Chagas’ disease. Arq. Bras. Cardiol.76(1), 75–96 (2001).
   PubMedGoogle Scholar
• Scanavacca MI, de Brito FS, Maia I et al. Brazilian Society of Cardiology. Guidelines for the evaluation and treatment of patients with cardiac arrhythmias. Arq. Bras. Cardiol.79(Suppl. 5), 1–50 (2002).
   PubMedGoogle Scholar
• Zatas CF, Perlino C, Caliendo A et al. Chagas Disease after organ transplantation – United States, 2001. MMWR Morb. Mortal. Wkly Rep.51(10), 210–212 (2002).
   PubMedGoogle Scholar
• Mascola L, Kubak B, Radhakrishna S et al. Chagas disease after organ transplantation-Los Angeles, California, 2006. MMWR Morb. Mortal. Wkly Rep.55(29), 798–800 (2006).
   PubMedGoogle Scholar
• Kun H, Moore A, Mascola L et al. Transmission of Trypanosoma cruzi by heart transplantation. Clin. Infect. Dis.48, 1534–1540 (2009).
   PubMed Web of Science ®Google Scholar
• Solves P, Parada C, Roig R, Hernandez MC, Rodriguez R, and Prat I. Chagas disease screening in cord blood donors. Transfusion49, 1023–1024 (2009).
   PubMedGoogle Scholar
• El-Sayed NM, Myler PJ, Bartholomeu DC et al. The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease. Science309, 409–415 (2005).
   PubMed Web of Science ®Google Scholar
• Villar JC, Marin-Neto JA, Ebrahim S, Yusuf S. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. Cochrane Database Syst. Rev.1, CD003463 (2002).
   Google Scholar
• Rassi A, Luquetti AO, Rassi Jr A et al. Specific treatment for Trypanosoma cruzi: lack of efficacy of allopurinol in the human chronic phase of Chagas disease. Am. J. Trop. Med. Hyg.76, 58–61 (2007).
   PubMed Web of Science ®Google Scholar
• Apt W, Arribada A, Zulantay I et al. Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the results of clinical and parasitological examination 11 years post-treatment. Ann. Trop. Med. Parasitol.99, 733–741 (2005).
   PubMed Web of Science ®Google Scholar
• Ferraz ML, Gazzinelli RT, Alves RO, Urbina JA, Romanha AJ. The anti-Trypanosoma cruzi activity of posaconazole in a murine model of Chagas disease is less dependent on gamma interferon than that of benznidazole. Antimicrob. Agents Chemother.51, 1359–1364 (2007).
   PubMed Web of Science ®Google Scholar
• Urbina JA, Payares G, Sanoja C, Lira R, Romanha AJ. In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease. Int. J. Antimicrob. Agents21, 27–38 (2003).
   PubMed Web of Science ®Google Scholar
• Corrales M, Cardozo R, Segura MA, Urbina JA, Basombrio MA. Comparative efficacies of TAK-187 a long-lasting ergosterol biosythesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas’ disease. Antimicrob. Agents Chemother.49, 1556–1560 (2005).
   PubMed Web of Science ®Google Scholar
• Marin-Neto JA, Rassi Jr A, Morillo CA et al. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologoc treatment in Chagas’ cardiomyopathy: The Benznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am. Heart J.156, 37–43 (2008).
   PubMed Web of Science ®Google Scholar